棕榈酸帕利哌酮PP1M治疗精神分裂症的药物经济学研究进展

Research process in pharmacoeconomic evaluation of paliperidone palmitate(PP1M)in the treatment of schizophrenia

目的系统总结棕榈酸帕利哌酮(PP1M)治疗精神分裂症的药物经济学相关研究结果,为抗精神病药的临床应用提供依据。方法系统检索Taylor&Francis、ScienceDirect、PubMed、Embase、CBM、中国知网和万方数据库等,检索时间从建库至2019年12月,纳入2015~2019年棕榈酸帕利哌酮(PP1M)药物经济学相关的文献,并参照综合卫生经济学评价报告准则(CHEERS)量表评估文献质量。结果共纳入14篇对照研究,主要评价内容包括棕榈酸帕利哌酮(PP1M)相比其他抗精神病药在疗效、成本节约和质量调整生命年(QALYs)等方面的差异。多数研究结果支持棕榈酸帕利哌酮(PP1M)更具优效性,且通过敏感性分析验证了结果的稳定性。结论当前抗精神病药物中,棕榈酸帕利哌酮(PP1M)在治疗精神分裂症方面具有良好的药物经济学优势,同时棕榈酸帕利哌酮(PP3M)的成本效果优势较为明显。

Objective To systematically review the results of pharmacoeconomics-related studies on the treatment of schizophrenia with paliperidone palmitate(PP1 M),so as to provide evidence for the clinical application of antipsychotics.Methods Taylor&Francis,ScienceDirect,PubMed,Embase,CBM,CNKI and Wanfang databases were systematically searched from their establishment to December 2019,and the literatures related to pharmacoeconomics of paliperidone palmitate(PP1 M)from 2015 to 2019 were included.The quality of literatures was evaluated with reference to Consolidated Health Economic Evaluation Reporting Standards(CHEERS)scale.Results A total of 14 controlled studies were included to evaluate the efficacy,cost savings,and Quality Adjusted Life Years(QALYs)of paliperidone palmitate(PP1 M)as compared to other antipsychotics.Most of the results supported the superior efficacy of paliperidone palmitate(PP1 M),and the stability of the results was verified by sensitivity analysis.Conclusion Among the current antipsychotic drugs,paliperidone palmitate(PP1 M)has a good pharmacoeconomic advantage in the treatment of schizophrenia.Meanwhile,the cost-effective advantage of paliperidone palmitate(PP3 M)is more obvious.